Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
D2.150 - Safety and efficacy of a 7-week immunotherapy protocol with aluminum hydroxide adsorbed bee venom
D2.159 - Real-World Protective Effects of Epicutaneous Immunotherapy in Peanut-allergic Toddlers
D2.149 - EFFECTIVENESS AND SAFETY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY WITH Pru p3 EXTRACT IN PATIENTS WITH LTP ALLERGY
D2.151 - Study design for A multicenter, open label, randomized Study to inveStigate the effIcacy of Subcutaneous immunoTherapy combined with vitamin D3 in children and adolescent patients with allergic rhinitis (ASSIST study)
D2.152 - Study design for the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders: a multicenter prospective observational study (CALM study)
D2.153 - Allergenicity and Immunogenicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus‐Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy
D2.154 - Real-life observational study on the effectiveness of a broad-spectrum allergen product in unresponsive pediatric patients
D2.155 - Factors associated with higher serum IgG4 response in children treated with allergen immunotherapy
D2.156 - Study on the Effect of the Mucosal Vaccine MV130 on Innate Immunity Factors in School-Age Children
D2.157 - Peanut allergen-loaded microneedle array patch modulates the immune response to peanut allergy in Balb/c and C3H/HeJ mouse model
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download